1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Shionogi & Co., Ltd. - Product Pipeline Review - 2015

Shionogi & Co., Ltd. - Product Pipeline Review - 2015

  • September 2015
  • -
  • Global Markets Direct
  • -
  • 68 pages

Shionogi & Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Shionogi & Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Shionogi & Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shionogi & Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Shionogi & Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Shionogi & Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Shionogi & Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Shionogi & Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Shionogi & Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shionogi & Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Shionogi and Co., Ltd. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Shionogi and Co., Ltd. Snapshot 7
Shionogi and Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Shionogi and Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Shionogi and Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Shionogi and Co., Ltd. - Pipeline Products Glance 17
Shionogi and Co., Ltd. - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Shionogi and Co., Ltd. - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Shionogi and Co., Ltd. - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Discovery Products/Combination Treatment Modalities 22
Shionogi and Co., Ltd. - Drug Profiles 23
lusutrombopag 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
naldemedine 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
oxycodone hydrochloride ER 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
S-414114 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
S-555739 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
S-588410 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
S-237648 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
S-646240 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
S-649266 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
S-707106 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
STG-120 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
S-222611 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
S-488210 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
doripenem 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
hydrocodone bitartrate ER 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
S-010887 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
S-033188 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
S-117957 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
S-120083 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Abuse Deterrent Combination Hydrocodone Program 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Small Molecule to Agonize CB2 for Pruritus 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Small Molecule to Antagonize NPY5R for Obesity 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Small Molecules for Mycobacterium Tuberculosis 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Shionogi and Co., Ltd. - Pipeline Analysis 50
Shionogi and Co., Ltd. - Pipeline Products by Target 50
Shionogi and Co., Ltd. - Pipeline Products by Route of Administration 52
Shionogi and Co., Ltd. - Pipeline Products by Molecule Type 53
Shionogi and Co., Ltd. - Pipeline Products by Mechanism of Action 54
Shionogi and Co., Ltd. - Recent Pipeline Updates 55
Shionogi and Co., Ltd. - Dormant Projects 59
Shionogi and Co., Ltd. - Dormant Projects 59
Shionogi and Co., Ltd. - Discontinued Pipeline Products 60
Discontinued Pipeline Product Profiles 60
doripenem 60
lusutrombopag 60
S-234462 60
S-288310 61
S-444823 61
S-488410 61
S-5751 61
S-777469 61
S-8510 61
teceleukin 61
velneperit 61
Shionogi and Co., Ltd. - Company Statement 62
Shionogi and Co., Ltd. - Locations And Subsidiaries 63
Head Office 63
Other Locations and Subsidiaries 63
Shionogi and Co., Ltd. - Key Manufacturing Facilities 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables
Shionogi and Co., Ltd., Key Information 7
Shionogi and Co., Ltd., Key Facts 7
Shionogi and Co., Ltd. - Pipeline by Indication, 2015 9
Shionogi and Co., Ltd. - Pipeline by Stage of Development, 2015 11
Shionogi and Co., Ltd. - Monotherapy Products in Pipeline, 2015 12
Shionogi and Co., Ltd. - Partnered Products in Pipeline, 2015 13
Shionogi and Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 14
Shionogi and Co., Ltd. - Out-Licensed Products in Pipeline, 2015 15
Shionogi and Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015 16
Shionogi and Co., Ltd. - Pre-Registration, 2015 17
Shionogi and Co., Ltd. - Phase III, 2015 18
Shionogi and Co., Ltd. - Phase II, 2015 19
Shionogi and Co., Ltd. - Phase I, 2015 20
Shionogi and Co., Ltd. - Preclinical, 2015 21
Shionogi and Co., Ltd. - Discovery, 2015 22
Shionogi and Co., Ltd. - Pipeline by Target, 2015 51
Shionogi and Co., Ltd. - Pipeline by Route of Administration, 2015 52
Shionogi and Co., Ltd. - Pipeline by Molecule Type, 2015 53
Shionogi and Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 54
Shionogi and Co., Ltd. - Recent Pipeline Updates, 2015 55
Shionogi and Co., Ltd. - Dormant Developmental Projects,2015 59
Shionogi and Co., Ltd. - Discontinued Pipeline Products, 2015 60
Shionogi and Co., Ltd., Other Locations 63
Shionogi and Co., Ltd., Subsidiaries 64
Shionogi and Co., Ltd., Key Manufacturing Facilities 66

List of Figures
Shionogi and Co., Ltd. - Pipeline by Top 10 Indication, 2015 9
Shionogi and Co., Ltd. - Pipeline by Stage of Development, 2015 11
Shionogi and Co., Ltd. - Monotherapy Products in Pipeline, 2015 12
Shionogi and Co., Ltd. - Partnered Products in Pipeline, 2015 13
Shionogi and Co., Ltd. - Out-Licensed Products in Pipeline, 2015 15
Shionogi and Co., Ltd. - Pipeline by Top 10 Target, 2015 50
Shionogi and Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 52
Shionogi and Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 53
Shionogi and Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.